title: [Causation and treatment of infectious leucorrhoea at the Cocody University Hospital (Abidjan, Côte d'Ivoire)].
abstract: OBJECTIVE
  to determine the frequency of different bacteria causing infectious leucorrhoea and to calculate the percentage of cures after standard treatment.
  
  
  METHODS
  This 7-month prospective descriptive study took place from October 2003 through April 2004 in the gynaecology department of Cocody University Hospital and in the department of sexually-transmitted infections of the Pasteur Institute of Côte d'Ivoire. After identification of the organism causing each case of leucorrhoea, we prescribed treatment according to a standard protocol. Vaginal samples were taken after treatment and tested to assess its success.
  
  
  RESULTS
  The most frequent bacteria discovered, in descending order, were: Gardnerella vaginalis (47%), Candida albicans (29.4%), Chlamydia trachomatis (13.7%), Trichomonas vaginalis (6.9%), and Neisseria gonorrhoeae (2.9%). The overall cure rate was 87%. Treatment failure was most common for C. trachomatis (8 of 14 cases, 57.1%), N. gonorrhoeae (1 of 3 cases) and T. vaginalis (2 of 7 cases, 28.6%). Treatment was 100% effective for G. vaginalis and C. albicans.
  
  
  CONCLUSIONS
  The fight against sexually-transmitted infections should be intensified, and patients and physicians cautioned about use of doubtful generic drugs.
authors.affiliation: Service de gynécologie et d'obstétrique du CHU de Cocody, B.P.V. 13, Abidjan, Côte d'Ivoire. abauleth@hotmail.com
authors.forename: Raphaël
authors.initials: R
authors.lastname: Abauleth
authors.forename: Serge
authors.initials: S
authors.lastname: Boni
authors.forename: Alphonsine
authors.initials: A
authors.lastname: Kouassi-Mbengue
authors.forename: Joachim
authors.initials: J
authors.lastname: Konan
authors.forename: Salomon
authors.initials: S
authors.lastname: Deza
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D002177:Candidiasis / Q000175:diagnosis / Q000188:drug therapy; D002690:Chlamydia Infections / Q000175:diagnosis / Q000188:drug therapy; D002692:Chlamydia trachomatis / Q000302:isolation & purification; D007560:Cote d'Ivoire; D005260:Female; D006194:Gardnerella vaginalis / Q000302:isolation & purification; D006069:Gonorrhea / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D007973:Leukorrhea / Q000188:drug therapy / Q000382:microbiology* / Q000469:parasitology; D008875:Middle Aged; D011446:Prospective Studies; D012749:Sexually Transmitted Diseases / Q000175:diagnosis / Q000188:drug therapy; D016896:Treatment Outcome; D014247:Trichomonas Vaginitis / Q000175:diagnosis / Q000188:drug therapy; D014621:Vagina / Q000382:microbiology; D016585:Vaginosis, Bacterial / Q000175:diagnosis / Q000188:drug therapy
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000935:Antifungal Agents